Shareholder revolt at Mylan over Epipen-gouging CEO's $98M bonus

The board of directors at Mylan have rewarded former CEO Robert Coury with a $98m bonus as he steps into the executive chairman's role, having overseen a price-gouging scandal over the Epipens used by people prone to life-threatening allergic reactions. Read the rest